{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:25:18Z","timestamp":1780550718736,"version":"3.54.1"},"reference-count":10,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Brodalumab is a recombinant monoclonal antibody (IgG2) that binds with high affinity to the human interleukin\u201017 (IL\u201017) receptor A and blocks the biological activity of the proinflammatory cytokines IL\u201017A, IL\u201017F, IL\u201017A\/F heterodimer, and IL\u2010 25, resulting in inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti\u2010IL\u201017 class), and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>Retrospective analysis of a multicenter, observational study of real clinical practice including patients with moderate to severe plaque psoriasis in treatment with brodalumab. This cross\u2010sectional analysis includes information of patients between February 2019 and February 2022. A total of five tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed \u201cas observed\u201d using GraphPad Prism version 8.3.0 for Windows.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our study included 85 patients, 54 men (63.5%) and 31 women (36.5%), with moderate\u2013severe psoriasis treated with brodalumab. In order to evaluate the efficacy of brodalumab, our patients started with mean Psoriasis Area and Severity Index (PASI) values of 12.8 and body surface area (BSA) of 16.9, as well as a Dermatology Life Quality Index (DLQI) of 15.6, highlighting that they reported that the mean baseline visual analog scale (VAS) pruritus was 6.15. On week 52, mean PASI reached 1.26 and mean BSA 2.3, showing a clear stabilization and even sustained improvement regarding results on week 12. Concerning the brodalumab survival, we obtained 85.8% persistence at week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Brodalumab showed excellent results in the control of psoriasis in the mid\u2010term with an elevated number of patients maintaining treatment after 52\u2009weeks. There were no statistically significant differences in the efficiency, safety, or survival results of brodalumab between patients coming from previous therapies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.16527","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T21:30:07Z","timestamp":1670707807000},"page":"700-706","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Brodalumab: Efficacy, safety, and survival in mid\u2010term (52\u2009weeks) on real clinical practice in Andalucia, Spain"],"prefix":"10.1111","volume":"62","author":[{"given":"Manuel","family":"Galan\u2010Gutierrez","sequence":"first","affiliation":[{"name":"Department of Dermatology Hospital Universitario San Reina Sof\u00eda, IMIBIC  C\u00f3rdoba Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Font\u2010Ugalde","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias M\u00e9dicas y Quir\u00fargicas (Universidad de C\u00f3rdoba, Spain) Instituto Maim\u00f3nides de Investigaci\u00f3n en Biomedicina de C\u00f3rdoba (IMIBIC)  C\u00f3rdoba Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Padilla","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de Jerez  Cadiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Hernandez\u2010Montoya","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de Poniente  El Ejido Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Godoy","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Regional Universitario de M\u00e1laga  M\u00e1laga Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose C.","family":"Armario\u2010Hita","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de Puerto Real  Cadiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz\u2010Villaverde","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario San Cecilio  Granada Spain"},{"name":"Instituto Biosanitario de Granada (ibs.GRANADA)  Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2017.53.5.2613690"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1749546"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0888-4"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S211938"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14866"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16931"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15532"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00411-w"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2022.02.007"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.16527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T04:10:52Z","timestamp":1692677452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.16527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/ijd.16527"],"URL":"https:\/\/doi.org\/10.1111\/ijd.16527","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]},"assertion":[{"value":"2022-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}